Basel, Switzerland and Budapest, Hungary (PRWEB) October 12, 2021 Genedata, the leading provider of enterprise software solutions for biopharmaceutical
Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis
Share Article
Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020. BUDAPEST, Hungary (PRWEB) March 16, 2021 The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rheumatoid arthritis patients, before the first biological treatment initiation. This novel tool supports the decision making of stakeholders including rheumatologists, patients, payors, and drug developers.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder affecting around 1% of the worldwide population. Clinical therapeutic options are still limited in their efficacy.